RWM
MGX icon

Rialto Wealth Management’s Metagenomi Therapeutics MGX Stock Holding History

Rialto Wealth Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-305
Closed -$723 – 1819
2025
Q3 		$723 Hold
305
– – ﹤0.01% 1060
2025
Q2 		$452 Buy
+305
New +$478 ﹤0.01% 1201

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rialto Wealth Management's MGX Position: Q4 2025 in Review

Rialto Wealth Management sold out of Metagenomi Therapeutics (MGX) in Q4 2025, closing a stake of 305 shares — an estimated $723 sold.

Rialto Wealth Management first reported a position in MGX in Q2 2025 and held it in 2 quarters. The position peaked at $723 in Q3 2025. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

  • Rialto Wealth Management reported no remaining Metagenomi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rialto Wealth Management sold 305 Metagenomi Therapeutics shares in Q4 2025, an estimated $723.
  • Rialto Wealth Management first reported a position in Metagenomi Therapeutics in Q2 2025 and held it in 2 quarters.
  • Rialto Wealth Management's Metagenomi Therapeutics position peaked at $723 in Q3 2025.
  • 56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Rialto Wealth Management's 13F filing for Q4 2025, filed 12 Jan 2026.